ferumoxytol injection
A curated overview of publicly available publications and abstracts related to ferumoxytol and relevant imaging research.
Disclaimer: Content on this page is provided for informational purposes only and does not constitute medical advice. Please refer to the full prescribing information and applicable local regulations.
Multiple SPION formulations have been investigated in both preclinical and clinical settings, and some have reached commercialization.
Public review literature links growing interest to factors such as increased kidney disease burden and rising demand for diagnostic and therapeutic applications.
Within this broader SPION landscape, Feraheme® (ferumoxytol injection) was approved in the US in 2009 (and later approved in Canada and Europe). Beyond iron-related indications, ferumoxytol has also been explored in research and clinical trials for imaging applications (e.g., as an MRI contrast agent).
Paste a PubMed / ClinicalTrials.gov / PMC URL and the site will fetch page text and automatically generate EN / 简体 / 繁體 highlights.
PubMed, ClinicalTrials.gov, and PMC links are supported for automatic parsing and multilingual highlight generation. For other sources (conference sites, PDFs), you can still try pasting the link or contact us.
Click to open the original source (PubMed / Oxford Academic)
Ferumoxytol is a superparamagnetic iron oxide nanoparticle (SPION). Beyond its established use as an iron product, researchers are exploring its potential for non-invasive brain imaging—especially for visualizing neuroinflammation and vascular changes associated with dementia.
Note: This section is educational and does not imply an approved indication. For clinical use, refer to the approved labeling and prescribing information.
We can prepare materials for hospital education, conference decks, or internal presentations.